首页> 美国卫生研究院文献>Pathogens >Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective about the Mode of Action
【2h】

Sublingual Immunotherapy: How Sublingual Allergen Administration Heals Allergic Diseases; Current Perspective about the Mode of Action

机译:舌下免疫疗法:舌下过敏原疗法如何治愈过敏性疾病;关于行动方式的当前观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Owing to the successful application of sublingual immunotherapy (SLIT), allergen immunotherapy (AIT) has become one of the leading treatments for allergic diseases. Similar to the case with other AITs, such as subcutaneous and oral immunotherapies, not only the alleviation of allergic symptoms, but also the curing of the diseases can be expected in patients undergoing SLIT. However, how and why such strong efficacy is obtained by SLIT, in which allergens are simply administered under the tongue, is not clearly known. Various potential mechanisms, including the induction of blocking antibodies, T cell tolerance, regulatory B and T cells, CD103-CD11b+ classical dendritic cells, and CD206+ macrophages, and the reduction of innate lymphoid cells, mast cells, and basophils, have been suggested. Recently, through a comparative analysis between high- and non-responder patients of SLIT, we have successfully proposed several novel mechanisms. Here, we introduce our recent findings and summarize the current understanding of the mechanisms underlying the strong efficacy of SLIT.
机译:由于应用舌下免疫疗法(缝隙),过敏原免疫疗法(AIT)已成为过敏性疾病的主要处理之一。与其他灰质的情况类似,如皮下和口服免疫治疗,不仅可以缓解过敏症状,而且还可以预期患者进行狭缝的疾病的固化。然而,如何以及为何通过狭缝获得这种强疗效,其中过敏原在舌下施用,没有明确征生。已经提出了各种潜在机制,包括诱导阻断抗体,T细胞耐受性,调节性B和T细胞,CD103-CD11b +典型树突细胞和CD206 +巨噬细胞,以及未降低先天淋巴细胞,肥大细胞和嗜碱性粒细胞。最近,通过狭缝狭缝患者的比较分析,我们已成功提出了几种新机制。在这里,我们介绍了我们最近的调查结果,总结了目前对狭缝强效果的机制的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号